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The phosphorylation of IkB by the IKK complex
targets it for degradation and releases NF-kB for
translocation into thenucleus to initiate the inflamma-
tory response, cell proliferation, or cell differentiation.
The IKK complex is composed of the catalytic IKKa/b
kinases and a regulatory protein, NF-kB essential
modulator (NEMO; IKKg). NEMO associates with the
unphosphorylated IKK kinase C termini and activates
the IKK complex’s catalytic activity. However, de-
tailed structural information about the NEMO/IKK
interaction is lacking. In this study, we have identified
the minimal requirements for NEMO and IKK kinase
association using a variety of biophysical techniques
and have solved two crystal structures of theminimal
NEMO/IKK kinase associating domains. We demon-
strate that the NEMO core domain is a dimer that
binds two IKK fragments and identify energetic hot
spots that can be exploited to inhibit IKK complex
formation with a therapeutic agent.
INTRODUCTION
NF-kB is a ubiquitous transcription factor involved in the regula-
tion of cell signaling responses. Its activation can lead tomultiple
cellular outcomes in a context-dependent manner, including the
inflammatory response, cell proliferation, and cell differentiation.
Typically, the canonical NF-kB signaling cascade is initiated by
such stimuli as tumor necrosis factor a (TNFa), bacterial lipopoly-
saccharide (LPS), and genotoxic agents. A key regulatory ele-
ment in this signaling pathway is the multimeric IKK complex,
composed of catalytic kinase subunits IKKa and IKKb, and a reg-
ulatory subunit, called NEMO (IKKg, IKKAP1, and FIP3). The cat-
alytically active IKK complex phosphorylates IkB, leading to IkB
degradation and, ultimately, the nuclear translocation of NF-kB.
Inhibition of the NF-kB signaling pathway presents therapeutic
potential for reducing arthritis, asthma, autoimmune disease,
and certain cancers that result from NF-kB hyperactivation
(Karin and Delhase, 2000). The TNFa inhibitors Enbrel and Remi-
cade, therapeutics that block stimuli leading to NF-kB activation,
have been successful in treating arthritis and other autoimmune798 Structure 16, 798–808, May 2008 ª2008 Elsevier Ltd All rights rdiseases. Small molecule inhibitors of IKK complex assembly
could offer an alternative mode of inhibition of NF-kB activation
and, in addition, provide benefits of oral administration and
decreased risk of immunogenicity.
Although IKK complexes that range from 700 to 900 kDa have
been isolated (DiDonato et al., 1997; Mercurio et al., 1997;
Yamaoka et al., 1998; Zandi et al., 1997), the molecular compo-
sition and stoichiometry of the complex is amatter of debate. It is
possible that multiple forms of the complex exist, and there is
evidence that its composition varies in a stimulus-dependent
manner (Solt et al., 2007). Despite this uncertainty, it is well
established that NEMO is essential for the activation of the IKK
complex in the canonical NF-kB signaling pathway (Bonizzi
and Karin, 2004; Makris et al., 2000; Rudolph et al., 2000;
Schmidt-Supprian et al., 2000). The IKKa and IKKb kinases share
52% identity. Each contains a kinase domain, a leucine-zipper
motif through which the catalytic subunits dimerize, and a
helix-loop-helix domain followed by a C-terminal tail that, when
unphosphorylated, interacts with NEMO (Zandi et al., 1997).
The predominant form of the complex contains an IKKa/b heter-
odimer, but both IKKa and IKKb homodimers (Karin, 1999; Mer-
curio et al., 1997; Woronicz et al., 1997; Zandi et al., 1998) and,
recently, even monomeric IKKa and IKKb kinases (Fontan et al.,
2007) have been reported in association with NEMO. The pre-
dicted domain structure of NEMO includes two coiled-coil
regions (CC1 and CC2), a leucine zipper (LZ), and a C-terminal
zinc finger (ZF) (Figure 1A). The N-terminal CC1 region interacts
with the IKK kinase C-terminal tails (Ghosh and Karin, 2002; Leo-
nardi et al., 2000). Although the CC2 and LZ regions of NEMO
have been proposed as potential sites of trimerization (Agou
et al., 2002) or tetramerization (Tegethoff et al., 2003), the N-
terminal domain encompassing CC1 has been reported to exist
as a dimer (Marienfeld et al., 2006).
A considerable amount is known about the intermolecular
requirements for the association of the IKK C-terminal tail and
the N-terminal CC1 region of NEMO. The IKK-binding region of
NEMO has recently been confined to residues 47–120 (Marien-
feld et al., 2006). Replacement of the phosphoacceptor Ser68
within this region with a phosphoserine mimetic (glutamate) de-
creased dimerization of NEMO in immunoblot analysis of 293 cell
extracts and reduced IKKbbinding in vitro, whereas replacement
with cysteine or alanine enhanced the observed dimerization
(Palkowitsch et al., 2008). A C-terminal region of IKKb containing
a conserved sequence common to both IKKa and IKKbeserved
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NEMO/IKK-Associating Domain StructureFigure 1. Binding of NEMO and IKK Peptides
(A) Predicted structural regions of NEMO (aH, a helix; CC, coiled-coil; LZ, leucine zipper; ZF, zinc finger) with schematic of recombinant proteins produced;
binding to IKK a/b hybrid measured by FRET and denoted by (+) or ().
(B) Sequence alignment of IKKb (black), IKKa (blue), and IKKa/b hybrid peptides. Underlined residues indicate those comprising the NEMO-binding domain
(NBD). Red indicates the required W residues in the NBD. Magenta indicates helix-breaking residues G717 and G731 of IKKa.
(C) Binding of GST-NEMO proteins to biotinylated-IKK a/b hybrid in FRET assay. Error bars represent the standard deviation from the average.
(D) Untagged peptides titrated into GST-NEMO1–196 bound to biotinylated IKKa/b hybrid 44-mer peptide. Error bars represent the standard deviation from the
average. Peptide sequences are in Table 1.
(E) Competition binding curves of NEMO44–111, NEMO1–196, and NEMO78–111. Untagged, refolded proteins were titrated into GST-NEMO1–196 bound to
IKKa/b 44-mer hybrid.(L737DWSWL742), commonly referred to as the NEMO-binding
domain (NBD) (May et al., 2000), is critical for complex formation.
A cell-permeable peptide containing the NBD sequence pre-
vents formation of the IKK complex (May et al., 2002) and effec-
tively inhibits NF-kB activation in human cancer cell lines (Biswas
et al., 2004; Thomas et al., 2002) and in multiple cell-based and
animal models of inflammation (May et al., 2000; Tas et al., 2006).
Mutational analysis has identified D738, W739, and W741 within
the NBD as key binding determinants (May et al., 2002). Further-
more, phosphorylation of S740within theNBD reduces the asso-
ciationwith NEMO (May et al., 2002; Schomer-Miller et al., 2006).
In this study, we have defined the minimal complex of NEMO
and IKK using rationally truncated NEMO proteins and IKK-
derived fragments. Residues 44–111 of NEMO constitute the
minimal IKK interaction domain, and two crystal structures of
this domain complexed to IKK kinase fragments are presented.
The NEMO44–111-IKK peptide complexes observed in the crystal
structures as well as a larger N-terminal fragment NEMO1–196 areStructuredimeric. The crystal structure reveals the molecular details of the
association between NEMO and the IKK kinases, explains how
phosphorylation of certain serine residues in this region might
affect complex formation, and finally, suggests avenues for the
development of targeted small molecule therapeutic agents.
RESULTS
Minimal Binding Domains
A series of truncated IKKa and IKKb peptides was designed to
obtain a NEMO/IKK complex suitable for structural studies. A
hybrid IKKa/b peptide was constructed to understand the differ-
ences in affinity between IKKa and IKKb and to serve as a tool for
assays. The hybrid peptide (a/b, 44-mer) consists of 30 amino
acids derived from the C terminus of the IKKb sequence (701–
730 in IKKb numbering) followed by 14 amino acids derived
from IKKa (731–745 in IKKa numbering), including the conserved
NBD hexapepetide LDWSWL (Figure 1B). A biotinylated version16, 798–808, May 2008 ª2008 Elsevier Ltd All rights reserved 799
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derived peptides for NEMO proteins using an in vitro fluores-
cence resonance energy transfer (FRET) assay. In agreement
with previously published results (May et al., 2002), full-length
NEMO1–419 and NEMO1–196 both bind to this peptide, whereas
NEMO86–419 does not (Figure 1C). When tested in a competition
format, both the IKKa/b hybrid peptide and an IKKb-derived
peptide (IKKb [701–746]) bind NEMO1–196 with equivalent
binding affinities (IC50 values of 36 and 47 nM, respectively;
Figure 1D). The negative control, an IKKa/b hybrid peptide in
which the two tryptophan residues within the NBD hexapeptide
sequence were mutated to alanine (IKKa/b hybrid [W/A];
Table 1), did not compete for binding (Figure 1D).
N-terminal truncation of the IKKa/b hybrid peptide resulted in
significantly reduced binding to NEMO. The IKKa/b 19-mer and
IKKa/b 28-mer peptides bound NEMO1–196 with low micromolar
affinity, whereas the IKKa 11-mer peptide could not compete
with the IKK a/b 44-mer hybrid, up to a concentration of 100 mM
(data not shown). Though the IKKa 11-mer peptide did not
compete with the IKKa/b 44-mer hybrid, both biotinylated IKKa
and IKKb 11-mer hybrids bound to NEMO1–196 in the FRET
assay, whereas a D-amino IKKa/b 44-mer hybrid peptide did
not (see Figure S1A in the Supplemental Data available with
this article online). Furthermore, the biotinylated IKKa 11-mer
peptide bound to NEMO1–196 can be successfully displaced by
the IKKa 11-mer, IKKa/b 19-mer, and IKKa/b 28-mer peptides
with IC50 values of 39 mM, 20 mM, and 7 mM, respectively
(Figure S1B). Given the micromolar affinities of the truncated
peptides relative to nanomolar affinities of the longer peptides,
the IKKa/b hybrid 44-mer and the IKKb 45-mer peptides were
selected for structural studies.
Byuseofa rationaldesignapproach,NEMO44–111was identified
as the minimal region that retains high-affinity binding to IKK-de-
rived peptides. The results of these binding studies are summa-
rized in Figure 1A. NEMO truncation design was guided by previ-
ously published results in conjunction with secondary structure
prediction results (Combet et al., 2000; Wolf et al., 1997). The
NEMO constructs shown in Figure 1A were produced in iterative
rounds and were tested for binding to the IKKa/b hybrid peptide.
ThepredictedstructuredregionswithinNEMO1–196consistofahe-
lical fragment (49–94) and two coiled-coil regions (103–130 and
136–195) that are collectively referred to as CC1 (Figure 1A). Be-
cause it had been shown that NEMO44–419 retains IKK-binding ac-
tivity (May et al., 2000), residue 44was selected as the N terminus
of the first set of truncated NEMO constructs. NEMO1–419,
Table 1. IKK Peptide Sequences
IKKa/b hybrid PAKKSEELVAEAHNLCTLLENAIQDTVR
EQGNSMMNLDWSWLTE
IKKb(701–746) PAKKSEELVAEAHNLCTLLENAIQDTVREQD
QSFTALDWSWLQTE
IKKa/b hybrid (W/A) PAKKSEELVAEAHNLCTLLENAIQDTVREQ
GNSMMNLDASALTE
a/b-28-mer TLLENAIQDTVREQGNSMMNLDWSWLTE
a/b-19-mer TVREQGNSMMNLDWSWLTE
a-11-mer MMNLDWSWLTE
b-11-mer FTALDWSWLQT800 Structure 16, 798–808, May 2008 ª2008 Elsevier Ltd All rights reNEMO1–196, NEMO1–130, NEMO44–196, and NEMO44–130 were pro-
duced as N-terminal glutathione S-transferase (GST) fusion pro-
teins and were tested for IKK binding. All bound to biotinylated
IKKa/b hybrid peptide in the FRET assay (Figure 1C, NEMO44–196
not shown), indicating that neither the N-terminal 44 amino acids
nor the C-terminal residues past amino acid 130 are required for
IKK binding. C-terminal truncations designed to shorten
NEMO44–130 sequentially by three helical turns were introduced
at residues 118, 111, and 102. NEMO44–118 and NEMO44–111 re-
tained IKK peptide-binding activity, whereas NEMO44–102 did not
(Figure S1C). In a third round of design, N-terminal truncations be-
ginning at 78 (NEMO78–118, NEMO78–111, and NEMO78–102) were
produced through peptide synthesis but none were capable
of competing with NEMO1–196 for binding peptide (data not
shown) and thus were not considered for subsequent studies.
NEMO44–111 encompasses the residues required for IKK binding.
Refolding Studies
Although NEMO proteins cleaved from the GST-fusion partner
did retain IKK peptide-binding activity (data not shown), these
truncated NEMO proteins were of insufficient purity and
biochemical homogeneity for use in biophysical studies. There-
fore, refolding protocols were developed for NEMO1–196 and
NEMO44–111. Because of poor expression of GST-NEMO44–111,
the untagged NEMO44–111 was expressed in Escherichia coli as
insoluble inclusion bodies and was refolded in vitro. NEMO1–196
was cleaved from the GST-fusion partner, denatured, refolded,
and further purified. As a result, the purity of each refoldedprotein
was greater than 90%. Refolded NEMO1–196 and NEMO44–111
competed similarly with theGST-NEMO1–196 in the FRET binding
assay with IC50 values of 32 nM and 60 nM, respectively
(Figure 1E), confirming both that the refolded proteins retain
IKK-binding activity and that the properties required for IKK pep-
tide binding are maintained in the much shorter NEMO44–111.
Although the refolded NEMO44–111 was active in the FRET
peptide-binding assay, conformational heterogeneity of apo-
NEMO44–111 was observed by NMR (described in the next
section; Figure S2A) and size-exclusion chromatography (SEC)
analysis. Refolding of NEMO44–111 in the presence of the IKK a/b
hybrid peptide resulted in a homogeneous preparationmore suit-
able for analysis using biophysical techniques.
NMR Analyses of NEMO and NEMO/IKK Fragments
NMR was used to further assess the minimal requirements of
each fragment to form a homogeneous, well-ordered species
for crystallization. NMR spectra were collected and evaluated
for features that are consistent with a monodisperse sample
with few disordered regions. By use of 1H,15N correlation spec-
troscopy, 15N-labeled NEMO proteins were screened in the
presence or absence of the IKK a/b hybrid peptide, and the
NMR spectra were evaluated on the basis of the number of res-
onances visible, chemical shift dispersion, and line broadening
(Page et al., 2005). Proteins starting at residue 1 produced
NMR spectra with 40 very intense crosspeaks with poor dis-
persion (data not shown), whereas proteins starting at residue
44 did not display this characteristic. This finding was attributed
to a disordered N terminus of40 residues; therefore, residue 44
was selected as the N-terminal start site for crystallization con-
structs. Furthermore, spectra of apo-NEMO44–111 displayedserved
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NEMO/IKK-Associating Domain StructureFigure 2. NEMO1–196 and NEMO44–111/IKKa/b Hybrid Peptide Complex Are Dimeric
(A) Size-exclusion chromatogram of NEMO and molecular weight standards.
(B) Homogeneity plots of regions of the main peak integrated for molecular weight determination by SEC/LS. Normalized traces shown are refractive index (blue)
and 90 light scatter (green) and calculated molecular weight (red).
(C) Summary of molecular weight of complexes based on theoretical molecular weight calculation and experimental data.a small set of severely broadened crosspeaks (Figure S2A),
whereas the 1H,15N TROSY-HSQC spectrum of NEMO44–111
complexed with the IKK a/b hybrid peptide contained the appro-
priate number of crosspeaks for a single homogeneous species
in solution with dispersion characteristic of a folded protein (Fig-
ure S2B). NEMO44–111/IKK a/b peptide complex, which gave
high-quality NMR spectra, also formed crystals.
NEMO1–196 and NEMO44–111 Are Dimers that Bind IKK
with Similar Affinity
NEMO1–196 and NEMO44–111/IKK a/b hybrid complexes were
analyzed using SEC, light scattering, and analytical ultracentrifu-
gation. SEC followedby static light scattering yielded amolecular
weight of 45.7 kDa for NEMO1–196, which corresponds to a dimer,
and 25.7 kDa for the NEMO44–111/IKK a/b hybrid peptide
complex, which corresponds to two NEMO44–111 proteins and
two IKK peptides (Figure 2B). Compared with globular protein
standards on gel filtration, the apparent molecular weights of
the NEMO proteins were much larger than those measured by
light scattering (Figure 2A). This finding suggests that the
NEMO1–196 dimer and the NEMO44–111/IKK a/b hybrid complex
are elongated. Sedimentation equilibrium analytical ultracentri-
fugation was also used to measure the molecular weights of
the proteins in solution. NEMO1–196 and NEMO44–111/IKK a/b
hybrid peptide complex are single ideal species with molecular
weights of 45.9 kDa and 25.2 kDa, respectively (data not shown),Structurea finding that is in agreement with static light scattering results.
These data along with the calculated molecular weights of the
dimeric NEMO1–196 and the tetrameric NEMO44–111/IKK a/b
hybrid peptide complex are summarized in Figure 2C.
Structure Solution and Architecture of the NEMO/IKK
a/b Hybrid and NEMO/IKKb Complexes
The crystal structures of NEMO44–111/IKK a/b hybrid peptide
complex (to 2.25 A˚ resolution) and NEMO44–111/IKKb complex
(to 2.2 A˚ resolution) were determined (Table 2), and representa-
tive electron density for the NEMO44–111/IKKb complex is shown
in Figure 3. The structures reveal that both protein complexes
are heterotetramers consisting of a NEMO dimer and two IKK
peptides. In the NEMO44–111/IKKa/b hybrid peptide complex,
NEMO density extends from residues 49 to 109 in chain B and
from residues 49 to 109 in chain D. The IKK peptide density
extends from residues 705 to 743 in chain A and from residues
701 to 744 in chain C. The description that follows applies to
both the NEMO/IKKb peptide complex and the NEMO/IKKa/
b hybrid peptide complex, unless explicitly stated.
Theheterodimeric complex is anelongated andatypical parallel
four-helix bundle (Figure 4A). Each NEMOmolecule is a crescent-
shapedahelix. The helices packhead-to-head to formadimeriza-
tion interface at the N and C termini (residues 51–65 and 103–107)
with a slit-shaped aperture running down the length of the bundle
(Figures 4B, 4D, and 4E). The two IKK peptides bridge across the16, 798–808, May 2008 ª2008 Elsevier Ltd All rights reserved 801
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NEMO/IKK-Associating Domain StructureTable 2. Data Collection, Phasing, and Refinement Statistics
Data collection
IKKa/b hybrida IKKba
Space group P212121 P212121
Cell dimensions
a, b, c (A˚) 41.9, 105.6, 56.7 90, 90, 90
a, b, g () 44.8, 102.8, 50.7 90, 90, 90
Semet1 Semet2
Phasing
NEMO/IKKb
Native
NEMO/IKKa/b
Native Peak Inflection Remote Peak Inflection
Remote
low E
Remote
High E
Wavelength (A˚) 1.0 1.1 0.9794 0.9796 0.9577 0.9799 0.9799 1.000 0.9577
Resolution (A˚) 50–2.20 50–2.25 50–2.5 50–2.5 50–2.5 50–2.4 50–2.4 50–2.4 50–2.4
Rsym or Rmerge (%)
b 10.3 (56.7) 7.2 (39.6) 6.4 (45.8) 6.7 (48.7) 7.1 (51.7) 6.0 (56.5) 6.1 (59.1) 6.3 (66.6) 6.6 (66.4)
I/sIb 15.1 (2.2) 28.3 (1.7) 19.5 (2.4) 18.3 (2.1) 16.8 (1.9) 20.8 (2.1) 20.0 (1.8) 18.5 (1.4) 18.5 (1.5)
Completeness (%)b 99.1 (95.9) 93.4 (69.4) 99.6 (98.6) 99.4 (96.0) 99.6 (97.5) 98.5 (97.3) 98.5 (96.6) 98.2 (93.3) 98.5 (95.6)
Redundancy 5.3 7.9 3.7 3.8 3.8 3.9 3.9 3.8 3.8
Refinement NEMO44–111/IKKa/b hybrid NEMO44–111/IKKb hybrid
Resolution (A˚)b 38.9–2.25(2.66–2.25) 45.5–2.2 (2.5–2.2)
No. of reflectionsb 11,119 (587) 11,737(813)
Rwork/Rfree (%)
b 23.8/28.1 (25.7/35.5) 21.8/29.2 (25.137.3)
No. of atoms
Protein 1594 1623
Water 62 103
Average B-factors (A˚2) 41.3 16.2
Root mean squared deviations
Bond lengths (A˚) 0.022 0.025
Bond angles () 1.93 2.24
Ramachandron (%. residues)
Most favored 97.4 98.4
Additionally allowed 2.6 1.6
aOnly one crystal was used for each structure.
b Highest resolution shell is shown in parentheses.NEMOhelices,onbothsidesof thisaperture. The IKKpeptidesare
also mainly helical, except for an unwound region between 732
and 742, where the backbone is constrained by interactions
between side chain tryptophans and main chain amides (Figures
4A and 4C). This highly constrained nonhelical region of the IKK802 Structure 16, 798–808, May 2008 ª2008 Elsevier Ltd All rights rpeptide is unique and differentiates the NEMO/IKK association
domain from other characterized 4-helix bundles such as the
SNARE complexes (Fasshauer et al., 1998).
The IKK peptides themselves do not form a homodimer.
Instead, each IKK peptide associates loosely with one of theFigure 3. Final 2Fo  Fc Electron Density
Map Contoured at 1.0 s
(A) NBD region of IKKb peptide.
(B) N-terminal NEMO dimerization region. Chains
are color coded for NEMO (chain B, green; chain
D, pink) and for IKKb (chain A, blue; chain C,
yellow).eserved
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NEMO/IKK-Associating Domain StructureNEMO molecules at the N terminus but is tightly wedged
between the two molecules of the NEMO dimer at the C termi-
nus. To best describe the interactions made by the IKK peptide
we have assigned three regions within the peptide, designated
as helical (705–731), linker (732–736), and the NBD (LDWSWL,
737–742) (Figure 6B). The flat slit of the dimeric NEMO forms
two broad and extensive IKK-binding pockets, with approximate
volume of 800 A˚3. These cavities are termed the specificity
pockets and are lined by residues 85–101 of NEMO; each pocket
is occupied by the IKK peptide linker and theNBD. In the text that
follows, IKK residues are designated with a one-letter code, and
NEMO residues are designated with a three-letter code.
TheNEMOdimer isstabilizedbyhydrophobic interactionsat the
NandC termini (Figures 4B, 4D, and 4E). TheN-terminal dimeriza-
tion patch is more extensive with high degree of spatial and elec-
trostatic complementarity (Figure4E;Leu51:Leu51,Cys54:Cys54,
Glu57:Arg62, Leu61:Leu61, and Ile65:Ile65). TheCbs of theCys54
residues are separated by 4.35 A˚, which is too long for a disulfide
bond, because the ideal distance is 3.4–4.25A between Cb posi-
tions (Hazes and Dijkstra, 1988). The C-terminal patch comprises
only hydrophobic interfaces (Figure 4D; Leu103 and Val104:
Leu103 and Val 104, Leu107:Leu107). Intriguingly, the NEMO
dimer is not precisely symmetrical, because corresponding resi-
dues that form theC-terminal dimerization interface have different
side chain rotamers. One Phe97 side chain forms the floor of the
binding pocket for both peptides, and the other Phe97 forms the
wall of the binding pocket for one of the peptides. The Arg101
side chain of chain C makes a salt bridge to the IKK peptide
D738, but Arg101 of chain A does not make this interaction.
The NEMO specificity pocket forms few hydrogen-bond inter-
actions with the IKK peptide but interacts mainly with hydropho-
bic side chains (F or M734, W739, and W741) (Figures 5A and
5B). The three hydrophobic side chains are oriented toward
the specificity pocket and are organized by a unique IKK back-
Figure 4. TheNEMO/IKKbPeptide Complex
Is an Asymmetrical, Parallel Four-Helix
Bundle
(A) Overall structure of the complex. NEMO chains
(B and D; pink and green) form binding site for
linker and NBD of IKK chains (A and C; blue and
yellow). The box indicates the major site for IKK
interaction.
(B) NEMO dimer showing the hole that results from
stripping away IKK peptides.
(C) Close-up view of the IKK binding site with the
three hydrophobic residues (734, 739, and 741)
of IKK in sticks (blue and yellow) and NEMO
residues that form the IKK-binding site (green
surface).
(D) Close-up view of the NEMO dimerization
patches at the C-terminal regions of the helix.
(E) Close-up view of the NEMO dimerization
patches at the N-terminal regions of the helix.
bone conformation. The side chains of
D738 and S740 in the NBD form a salt
bridge that kinks the backbone. The
side chains of the two tryptophans in
the NBD sequence (W739 and W741)
each form hydrogen bonds with backbone carbonyls in the IKK
peptide (734 and 738, respectively). In an intermolecular interac-
tion, the third hydrophobic residue, F734 or M734, is directed
into the nonpolar pocket, and its backbone amide forms a
hydrogen bond with Glu89 of NEMO (Figure 5C). These interac-
tions result in the optimal placement of the three large IKK side
chains inside the NEMO pocket, yielding a high-affinity complex.
The intermolecular interactions between IKK and NEMO occur
via hydrogen bonding (Ser85:Q730, Glu89:S733, and the
F734 backbone amide, Arg101:D738) and hydrophobic interac-
tions (Leu93:F734, Phe92:T735, Met94:F734, Phe97:W739,
Ala100:W741, and Arg101:W741).
Conformational Similarity between the NEMO/IKKa/b
Hybrid Peptide and NEMO/IKKb Complexes
The two crystal structures described here contain selectivity
regions consisting of the linker and NBD derived from either
IKKa or IKKb, but in both cases, the N-terminal helical region is
derived from the IKKb sequence (Figure 1B; Table 1). A superpo-
sition of the selectivity regions of these two structures indicates
that the overall orientation of the four helices in the complex and
the shapes of the NEMO cavities are essentially identical
(Figure 5B). The overall RMSD of the Cas of these two com-
plexes is 1.13 A˚ for 203 a-carbons.
DISCUSSION
Organization and Implications for NEMO Regulation
of IKK Activity
Although NEMO is a large scaffolding protein involved in a num-
ber of protein-protein interactions, we demonstrate here that
a short stretch of residues in NEMO44–111 is necessary and suf-
ficient for IKK binding. The parallel arrangement of the helices
observed in the minimal complex places conformationalStructure 16, 798–808, May 2008 ª2008 Elsevier Ltd All rights reserved 803
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NEMO/IKK-Associating Domain Structureconstraints on the full IKK complex. The regions involved in com-
plex formation are at the N terminus of NEMO and the C terminus
of the IKKa and IKKb kinases. In addition, the kinases dimerize
through leucine zipper motifs N-terminal to this region, and
NEMO self-associates through leucine zipper motifs C-terminal
to this region. Such a complex could be elongated and have
a high apparent molecular weight by gel filtration, thus explaining
the measurement of 700–900 kDa by others.
The minimal interaction region of NEMO forms a dimer and
exhibits the same affinity for IKK peptides as does the larger
NEMO1–196 domain. Additionally, NEMO and IKK sequences
are highly conserved across several mammalian species in
both the NEMO dimerization regions and the IKK interaction re-
gions, suggesting that that these regions indeed constitute the
functional and structural core of the complex (Figure 6A). The
NEMO hydrophobic residues in the specificity pocket would be
exposed to water if one stripped the IKK peptides from the struc-
ture of the complex presented here, suggesting that the 44–111
region could be disordered, in a different conformation, or
masked in the absence of IKK. Although we have no direct ex-
perimental evidence in support of any of these models, our
NMR data on NEMO 44–111 do support the model that this region
of NEMO becomes ordered in the presence of bound IKK pep-
tide (Figure S2).
There are two intriguing features of the structure that may have
implications for regulation of NEMO binding. First, in both the
IKKa/b hybrid peptide and the IKKb core complex structures,
the two IKK peptides are not bound identically into the specificity
pockets. The asymmetry ismainly due to a repositioning of NEMO
side chain Phe97, which forms the floor of both specificity
pockets. This suggests possible crosstalk between the two sites,
on the basis of the orientation of the Phe97 side chain. Although
Figure 5. The Linker and NBD of IKKa
and IKKb Bind in a Hydrophobic Cleft
(A) Sequences of the linker and NBD for IKKa and
IKKb.
(B) Surface representation of NEMO with the
superimposed NBD and linker segments of the
IKKa/b hybrid peptide (magenta) and the IKKb
peptide (green). The surface is colored yellow for
hydrophobic surfaces, red for negatively charged
surfaces, and blue for positively charged surfaces.
Note that three hydrophobic residues (734, 739,
and 741) fit in the hydrophobic cleft. There is a
similar hydrogen bond between E89 of NEMO
and the 734 backbone amide of each IKK peptide.
(C) Intramolecular hydrogen bonding of the linker
and NBD of the IKK peptide, which constrains
the unique, unwound conformation. Included is
a cartoon of the three hydrophobic pockets and
the H-bond from Glu89 to the backbone of the
IKK linker region, which defines the pharmaca-
phores of this binding site.
the pockets are not structurally identical,
they appear to bind two IKK peptides
with similar affinity, because competition
data can be adequately fit to a 1-site
model (data not shown). Communication
between binding sites within NEMO could
possibly regulate theirmutual IKKbindingand/or release.Second,
the structure shows that Ser68, whose mutation to the phospho-
serine mimetic glutamate reduces dimerization and IKKb binding
(Palkowitsch et al., 2008), is buried in the hydrophobic core of
the dimer. If this serine is phosphorylated as a result of NEMO reg-
ulation, it is unlikely to form a complex because of charge-charge
repulsion.
NEMO has been shown to bind to IKKa, as well as IKKb,
although the interaction with IKKa has been reported to be
weaker (May et al., 2002). Superimposing the structures of the
NEMO/IKKa/b hybrid complex and the NEMO/IKKb complex
shows that the linker regions of IKKa and IKKb are interchange-
able (Figure 5B). The M734 and the F734 in the linker regions of
IKKa and IKKb, respectively, are equivalent in the manner in
which they bind to the third hydrophobic site in the specificity
pocket. This structural equivalence suggests that the difference
in affinity between the IKKa and IKKb kinases for NEMOcould in-
stead result from differences in the N-terminal helical region. We
have shown that removing part or the entire helical region of the
IKK peptides reduces their NEMO-binding affinity significantly. A
noncanonical helix or a sequence with reduced helical propen-
sity could also account for the reduced binding affinity of IKKa.
The presence of helix-breakers G717 and G731 in IKKa may
account for the reduced affinity of the IKKa kinase for NEMO
(Figure 1B).
Importance of NBD Residues
The structure further provides an explanation for the effects of
mutating the conserved NBD of IKK (LDWSWL) (May et al.,
2002). Mutation of W to F at 739 or 741 can maintain the integrity
of the structure and retain NEMO binding, but mutation of W to Y
is tolerable only at position 739. In addition to forming specific804 Structure 16, 798–808, May 2008 ª2008 Elsevier Ltd All rights reserved
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NEMO/IKK-Associating Domain StructureFigure 6. NEMO and IKK Sequence Alignments
(A) Sequence alignment of NEMO residues 44–111 from different mammalian species, highlighting deviations from the human sequence. The residues
contributing to NEMO dimerization are in red, and residues involved in formation of the IKK specificity pocket are in blue.
(B) Sequence alignment of IKKb residues 701–745 from different mammalian species denoting helical, linker, and NBD from the structure. The conserved
hydrophobic residues that constitute a hot spot are shown in red.hydrogen bonds to an IKK backbone, each tryptophan side
chain of the NBD is buried in the nonpolar NEMO cavity forming
aromatic interactions with Phe92 and Phe97. A mutation of W to
F at 739 or 741 canmaintain these interactions. However, Tyr will
incur a desolvation penalty upon burial in this hydrophobic cavity
and needs an appropriate hydrogen-bonding partner in the
pocket. Our modeling studies show that the side chain hydroxyl
of Y739 can form an additional intramolecular hydrogen bond
with the backbone carbonyl of F734 and retain the native back-
bone IKK conformation. In contrast, Y741 does not have an
appropriate hydrogen-bonding partner and will incur a desolva-
tion penalty upon burial. Hence, the model predicts that intro-
duction of a Y at 741 would destabilize the IKK conformation,
leading to reduced NEMO binding.
The structure also explains why L737 or L742 is required in the
NBD but mutation of both to alanine reduces binding. The struc-
ture suggests that both leucines form a seal around the trypo-
phan side chains to reduce the access of waters, and they also
help to wedge open the specificity pocket. It is possible that
either leucine can perform these functions, but loss of both
leucines is not tolerated.
Phosphorylation of the IKKC-terminal domainmaintains IKK in
a low, basal level of activity, possibly by reducing its interaction
with NEMO (Karin and Delhase, 2000; Schomer-Miller et al.,
2006). The structure explains this observation by identifying
a critical S740 intermolecular interaction that can be affected
by phosphorylation. On the basis of the structure, disruption of
the IKK S740-D738 hydrogen bond by phosphorylation of
S740 would alter the way the tryptophans could insert into the
NEMO specificity pocket and thus reduce NEMO-binding affin-
ity. Mutation of D738 to asparagine or glutamate, which can
maintain this intramolecular interaction, retains NEMO binding,Structurewhereas itsmutation to alanine, which cannot form this hydrogen
bond, reduces NEMO-binding affinity (May et al., 2002).
Selectivity Pocket and Hot Spots
Three regions in the IKK peptide contribute to binding affinity for
NEMO. However, the linker and NBD appear to form the more
critical interactions: mutagenesis of two tryptophans in the con-
served NBD causes a reduction in binding affinity of more than
two orders of magnitude (May et al., 2002), and we found from
the crystal structure that a hydrophobic residue from the linker
region forms a third strong hydrophobic contact with NEMO.
An alignment of the IKKb sequences from many species shows
that the hydrophobic residue at position 734 is conserved
(Figure 6B). Furthermore, in the crystal structures, the M734 of
the IKKa sequence occupies the same space as the F734 of
IKKb (Figure 5B). These observations lead us to propose a phar-
macophore model consisting of three hydrophobic motifs de-
rived fromW741,W739, andM/F 734 side chains and a hydrogen
bond donormimicking the IKK 734 backbone amide, which inter-
acts with Glu89, as a way of describing the important contacts
needed in a small molecule or peptide-based inhibitor to recapit-
ulate the properties of the bound IKK peptide (Figure 5C). Con-
sequently, the critical interaction motif in IKK should be defined
as being larger than the NBD (LDWSWL) motif previously cited
(May et al., 2000).
The localization of key residues (M/F 734, W739, andW741) in
a restricted area of the protein-protein interface and the effect of
alanine substitutions on binding affinity (100-fold reduction in our
assay for W739,741) define the region as a hot spot for the inter-
action (May et al., 2002). From a structural perspective, hot spots
are near the geometric center of an interface and often contain
the amino acids tryptophan, tyrosine, and arginine (Bogan and16, 798–808, May 2008 ª2008 Elsevier Ltd All rights reserved 805
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NEMO/IKK-Associating Domain StructureThorn, 1998). The NEMO/IKK interaction surface is quite exten-
sive and removal of the IKK helix region provides a significant
part of this binding energy (Figure 2C). However, disruption of
these hot spot residues is sufficient to prevent the association
(May et al., 2002). A second characteristic of a hot spot is the
formation of a seal by residues surrounding the interface, which
excludes water from the hydrophobic residues. In NEMO, this
watertight seal is formed by side chains that interact with the
exposed polar side chains of the peptide: Arg101 of NEMO
with D738, Glu89 of NEMO with S733 and the 734 backbone
amide, and Lys90 of NEMO with the 732 carbonyl. As a result,
there are very few waters in the binding site as observed at
2.2 A˚ resolution. The sum of these characteristics of the binding
interface suggests that the selectivity pocket, which binds the
linker and NBD of IKK, could be the target of a small molecule
therapeutic agent. Inhibition of IKK signaling by disruption of
the NEMO/IKK interaction could be beneficial in a variety of
autoimmune disorders and cancers; this work opens new ave-
nues for the rational design and optimization of such molecules.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
DNA encoding the full-length NEMO1–419 was obtained by PCR from the
IMAGE clone 4651870. GST-NEMO expression vectors were generated by
cloning NEMO-encoding fragments into pGEX-6p-1 (GE Healthcare). The pro-
teins were produced in BL21(DE3) cells grown at 20C and were induced with
1 mM isopropyl-b-D-thiogalactopyranoside (IPTG). Because of poor expres-
sion in the T7-based pGEX vector, GST-NEMO1–419 and GST-NEMO86–419
were subcloned into pBAD-HISA (Invitrogen) and were expressed in E. coli
One Shot TOP 10 cells (Invitrogen) grown at 20C and induced with 0.002%
arabinose. Cells were lysed by French press, and clarified lysate was purified
on Glutathione Sepharose 4 Fast Flow (GE Healthcare). GST-NEMO1–196 was
denatured with 10 M Guanidine-HCl, was refolded by dialysis into refolding
buffer (10 mM TRIS [pH 8], 50 mM NaCl, 5 mM DTT, and 1 mM EDTA), and
was purified by anion-exchange chromatography (Q Sepharose Fast Flow,
GE Healthcare) followed by SEC (Superdex 200, GE Healthcare). GST-free
NEMO1–196 wasmade by cleaving the fusion proteinwith PreScission Protease
enzyme (GE Healthcare) and removing GST and uncleaved GST-NEMO1–196
with Glutathione Sepharose. Untagged NEMO1–196 was denatured, refolded,
and purified by anion-exchange and SEC, as described above for GST-
NEMO1–196.
Expression vectors for untagged NEMO proteins were generated by cloning
NEMO encoding fragments into pET 11a, and for NEMO44–111, a tryptophan
was engineered at residue 45 for tracking the protein by UV absorbance. Pro-
tein was produced in BL21(DE3) cells grown at 37C and induced with 1 mM
IPTG. Selenomethionine-substituted NEMO44–111 was produced B834 cells
(methionine auxotroph, Novagen) using a standard procedure (Leahy et al.,
1992) and was induced the same way. NEMO was isolated and solubilized
from inclusion bodies (Supplemental Experimental Procedures) and was puri-
fied by reverse-phase chromatography on a Sep-Pak C8 column (Millipore).
Genes encoding IKKa/b hybrid and IKKb (701–746) peptides were con-
structed by ligation of synthetic oligos, amplified, and cloned into pET32a
(Novagen) for expression as His6-thioredoxin fusion proteins containing an
enterokinase cleavage site. The proteins were produced in BL21(DE3) cells
as described above for NEMO44–111 protein. Cells were lysed by stirring over-
night in 8M urea, 100mM sodium phosphate, and 10mMTRIS (pH 8.0) at 4C.
The fusion protein was purified from clarified lysate on Ni-NTA agarose
(QIAGEN) in denaturing conditions; was refolded by dialysis against 50 mM
TRIS (pH 8), 50 mM NaCl, and 5 mM 2-mercaptoethanol; and was cleaved
with enterokinase (EMD Biosciences). The His-tagged thioredoxin portion
was removed using Ni-NTA agarose, and the peptide was denatured with
8 M guanidinium hydrochloride and was further purified on a reverse-phase
sep-pak C8 column.806 Structure 16, 798–808, May 2008 ª2008 Elsevier Ltd All rights reIKK Synthetic Peptides
The IKK peptides were synthesized and purified at Mimotopes (sequences re-
ported in Table 1). N-terminally biotinylated IKK a/b hybrid peptides 44-mer
and 11-mer (Table 1) were synthesized by solid-phase synthesis using
standard Fmoc/tBu protocol and were purified to greater than 95% homoge-
neity by RP-HPLC.
NEMO/Peptide Complex Preparation
For crystallization, NEMO44–111 was denatured and refolded by dialysis as de-
scribed for GST-NEMO1–196. Sodium chloride (150 mM) and 1.1 molar excess
lyophilized peptide were added to the protein, and the mixture was incubated
at 37C for 30 min and concentrated to 10 mg/ml. For NMR studies, NEMO/
IKK peptide complexes were prepared by dissolving lyophilized NEMO44–111
protein in an excess of IKK peptide dissolved in NMR buffer (50mMphosphate
buffer [pH 6.8], 95% H2O and 5% D2O, 50 mM NaCl, 0.02% NaN3, and 5 mM
DTT-D10). The complex was then purified by size exclusion chromatography to
ensure a 1:1 complex.
FRET Activity Assays
A FRET assay was used to detect NEMO peptide binding. In the direct binding
format, 10 nM GST-NEMO was incubated with increasing amounts of biotiny-
lated IKK peptide for 30 min at room temperature. The detection agent (50 nM
streptavidin-conjugated APC and 10 nM LANCE Europium-W1024 labeled
anti-GST, Perkin Elmer) was incubated for 30 min at room temperature, and
the FRET signal was read on an LJL Analyst AD (Molecular Devices). In a
competition format, 10 nMGST-NEMO1–196 was bound to 200 nM biotinylated
peptide in binding buffer.
Unlabeled peptides or untagged NEMO proteins were titrated into the
mixture, incubated for 30min at room temperature, and detected as described
above.
Analytical Ultracentrifugation
Sedimentation equilibrium experiments were conducted at 20C in a Beck-
man Optima XL-I ultracentrifuge (Beckman, Palo Alto, CA), using an An50
Ti 8-hole rotor and 12 mm six-channel charcoal-filled Epon centerpieces.
Samples ranging in concentration from 0.05 to 0.7 mg/ml were centrifuged
at 15,000, 22,000, and 30,000 rpm for NEMO1–196, and 25,000 and 35,000
rpm for NEMO44–111/IKKa/b hybrid complex. The sedimentation profiles
were monitored at wavelengths of 228, 280, and 290 nm. Data were analyzed
using the software NONLIN (Johnson et al., 1981), and molecular weights of
the complexes were calculated using the program SEDNTERP (Laue et al.,
1992).
SEC/Static Light-Scattering Analysis
SEC was performed using a 300 3 7.8 mm BioSep SEC 2000 column
(Phenomenex) in 20 mM sodium phosphate (pH 7) and 150 mM NaCl (PBS)
with a Waters Alliance HPLC instrument coupled to a refractive index detector
(Waters, Milford, MA) and light-scattering detector (PD2000, Precison Detec-
tors, Bellingham, MA). The weight average molar mass was determined using
the Precision Detector Software. The system was calibrated using BSA
assuming isotropic light scattering.
Nuclear Magnetic Resonance
The protein samples for NMR were uniformly labeled with 13C, 2H, or 15N by
growing cells in minimal salt media containing 13C6-D-glucose and 99.9%
D2O and
15NH4Cl (Cambridge Isotope Laboratories, Spectra Stable Isotopes).
NMR spectra were recorded on samples of concentration varying between 0.1
and 0.6mM, at 35C. All datawere acquired on aBruker Avance600 spectrom-
eter equipped with a cryogenic probe. Construct screening utilized 15N-la-
beled protein and 1H,15N-HSQC (Bax et al., 1983) or 1H-15N-TROSY
(Pervushin et al., 1997) experiments.
Crystallization and Structure Solution
Crystals of NEMO/IKK a/b hybrid peptide complex were formed under silicon
oil using 1:1 volume ratio of 10mg/ml protein solution to crystallization solution
of 35%Peg 8K, 0.1M Tris (pH 8), 0.2M ammonium chloride, and 10mMdithio-
threitol (DTT). The crystals were cryoprotected in 35% Peg4K, 10% ethylene
glycol, 0.1 M Tris (pH 8), 0.1 M ammonium chloride, and 10 mM DTTserved
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were grown in vapor-diffusion hanging-drop set-up at 20C using 1:1 volume
ratio of 10 mg/ml complex with a well solution of 30% Peg 4K, 0.1 M Tris (pH
8.5), 0.2 M MgCl2, 10 mM DTT, and 1.4 mM deoxybigchap. The crystals were
cryoprotected in 30% Peg4K, 0.1 M Tris (pH 8.5), 0.2 M MgCl2, 10 mM DTT,
and 10% glycerol and were transferred into liquid nitrogen.
The crystals belong to space group P212121 with unit cell dimensions as
follows: a = 42.1A˚, b = 105.6 A˚, c = 56.8 A˚, and a = b = g = 90, which are con-
sistent with a 2:2 ratio of NEMO and IKK peptide molecules per asymmetric
unit (Table 2). Native data were collected at beamline X8C at the National
Synchrotron Light Source (Upton, NY) at wavelength 1.1 A˚. Two MAD experi-
ments were conducted on selenomethionine-NEMO/unlabeled IKK a/b hybrid
peptide complex crystals using three or four wavelengths near the selenium K
edge (Table 2). Data processing to 2.5 A˚ was performed with the HKL2000
(Otwinowski and Minor, 1997) program package. The structure of the
NEMO/IKK a/b hybrid complex was solved by multiple anomalous dispersion
phasing using SOLVE (Terwilliger and Berendzen, 1999), which identified two
selenium sites per asymmetric unit and produced phases with a figure of merit
of 0.70 to 3.2A˚. Solvent flattening with RESOLVE (Terwilliger and Berendzen,
1999) using a solvent content of 60% resulted in an improvement in phasing
with an overall figure of merit of 0.79 to 3.2 A˚. The initial model was traced
by hand, using O software (version 8) (Jones et al., 1991), and was subjected
to rounds of refinement using an MLHL target and reserving 5% of the reflec-
tions for the test set. The availability of native data to 2.25 A˚ resolution allowed
re-refinement against an MLF target and refinement proceeded to conver-
gence. The structure was then refined with REFMAC5 (Murshudov et al.,
1997) and by removing side chains with low occupancy. The last cycles of
refinement were performed with TLS restraints as implemented in REFMAC5
in which the optimal number of groups was defined according to TLS Motion
Determination (version 0.8.1) (Painter and Merritt, 2006a, 2006b). The final
model of the NEMO/IKK a/b hybrid complex has an R factor of 23.7% and
an Rfree of 28.1% and consists of residues B49–B109 and D49–D110 of
NEMO (chains B and D), residues A705–A743 and N-terminal Met-Ala-
C701–C743 of the IKK peptide (chains A and C), and 62 waters. The Wilson
plot overall B for this complex is 70.6 A˚2.
The NEMO/IKKb peptide complex structure was solved by molecular
replacement using the NEMO/ IKK a/b hybrid complex structure as a search
model in MOLREP (Vagin and Teplyakov, 1997) and was refined as described
above for the hybrid complex. The final model of the NEMO/IKKb complex has
an R factor of 20.8% and an Rfree of 29.4% and consists of residues B49–B109
and D49–D110 of NEMO (chains B and D), residues A705–A743 and C702–
C743 of the IKKb peptide (chains A and C), and 103 waters. The Wilson plot
overall B for this complex is 43.9 A˚2. The quality of the two models was
analyzed by PROCHECK (Laskowski et al., 1993) (Table 2).
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